PL4159205T3 - Novel pharmaceutical composition - Google Patents

Novel pharmaceutical composition

Info

Publication number: PL4159205T3
Authority: PL; Poland
Prior art keywords: pharmaceutical composition; novel pharmaceutical; novel; composition; pharmaceutical
Prior art date: 2010-12-20

Application number

PL22209107.6T

Other languages

Polish (pl)

Inventor

Douglas J. De Marini

Ngocdiep T. Le

Francisco HENRIQUEZ

Lihong Wang

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-20

Filing date

2011-12-20

Publication date

2024-06-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4159205(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-20 Application filed by Novartis Ag filed Critical Novartis Ag

2024-06-24 Publication of PL4159205T3 publication Critical patent/PL4159205T3/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL22209107.6T 2010-12-20 2011-12-20 Novel pharmaceutical composition PL4159205T3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201061424967P	2010-12-20	2010-12-20

Publications (1)

Publication Number	Publication Date
PL4159205T3 true PL4159205T3 (en)	2024-06-24

Family

ID=46314827

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL22209104.3T PL4159204T3 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition
PL11849974T PL2654736T3 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition
PL22209107.6T PL4159205T3 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL22209104.3T PL4159204T3 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition
PL11849974T PL2654736T3 (en)	2010-12-20	2011-12-20	Novel pharmaceutical composition

Country Status (38)

Country	Link
US (5)	US8580304B2 (en)
EP (4)	EP4159204B1 (en)
JP (2)	JP6126014B2 (en)
KR (1)	KR101911109B1 (en)
CN (1)	CN103998041B (en)
AR (2)	AR084102A1 (en)
AU (1)	AU2011349422B2 (en)
BR (1)	BR112013015602B1 (en)
CA (1)	CA2822701C (en)
CL (1)	CL2013001779A1 (en)
CR (1)	CR20130352A (en)
CY (1)	CY1123376T1 (en)
DK (3)	DK4159204T3 (en)
DO (1)	DOP2013000138A (en)
EA (1)	EA025198B1 (en)
ES (3)	ES2820536T3 (en)
FI (2)	FI4159204T3 (en)
HR (3)	HRP20240564T1 (en)
HU (3)	HUE066526T2 (en)
IL (1)	IL226855A (en)
JO (1)	JO3594B1 (en)
LT (3)	LT4159204T (en)
MA (1)	MA34883B1 (en)
MX (1)	MX2013007073A (en)
MY (1)	MY170501A (en)
NZ (1)	NZ612157A (en)
PE (1)	PE20140040A1 (en)
PH (1)	PH12013501209A1 (en)
PL (3)	PL4159204T3 (en)
PT (3)	PT4159204T (en)
RS (2)	RS65497B1 (en)
SG (1)	SG191054A1 (en)
SI (3)	SI2654736T1 (en)
TW (1)	TWI505828B (en)
UA (1)	UA113158C2 (en)
UY (1)	UY33818A (en)
WO (1)	WO2012088033A2 (en)
ZA (1)	ZA201304189B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI505828B (en)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	Novel pharmaceutical composition
DK2884979T3 (en)	2012-08-17	2019-09-02	Hoffmann La Roche	Combination treatments for melanoma including administration of cobimetinib and vemurafenib
PE20151024A1 (en) *	2012-11-30	2015-07-27	Glaxosmithkline Llc	NEW PHARMACEUTICAL COMPOSITION
WO2015019125A1 (en) *	2013-08-05	2015-02-12	Societe De Developpement Et De Recherche Industrielle	Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (en) *	2013-11-25	2014-05-28	镇江圣安医药有限公司	Derivative of pyridine and (4,3-d) pyrimidine-1(2H)-base phenyl acetamide and application thereof
WO2015081566A1 (en) *	2013-12-06	2015-06-11	杭州普晒医药科技有限公司	Crystalline forms of trametinib and solvate thereof, preparation method therefor, pharmaceutical composition comprising same and use thereof
EP2913048A1 (en)	2014-02-27	2015-09-02	ratiopharm GmbH	Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) *	2015-02-05	2016-08-11	Boryung Pharmaceutical Co., Ltd	Tablet and method of preparing the same
KR101545268B1 (en)	2015-02-05	2015-08-20	보령제약 주식회사	Tablet and method of preparing the same
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20170020880A1 (en) *	2015-07-22	2017-01-26	Hetero Research Foundation	Pharmaceutical compositions of trametinib
CN109789141B (en) *	2016-08-10	2022-08-26	豪夫迈·罗氏有限公司	Pharmaceutical compositions comprising Akt protein kinase inhibitors
RU2627692C1 (en)	2016-10-10	2017-08-10	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidine-1-il]-phenyl}-cyclopropanecarboxamide dimethylsulfoxide solvate as mek1/2 inhibitor
CA3041561A1 (en) *	2016-11-25	2018-05-31	Jiangsu Hengrui Medicine Co., Ltd.	Pyridone derivative pharmaceutical composition and preparation method thereof
WO2018203219A1 (en)	2017-05-02	2018-11-08	Novartis Ag	Combination therapy
EP4563150A3 (en)	2019-05-13	2025-07-23	Novartis AG	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
WO2021007487A1 (en)	2019-07-11	2021-01-14	Praxis Precision Medicines, Inc.	Formulations of t-type calcium channel modulators and methods of use thereof
CA3149796A1 (en)	2019-08-02	2021-02-11	Onehealthcompany, Inc.	Anti-cancer agents for the treatment of canine cancers
RU2749719C1 (en) *	2020-10-08	2021-06-16	Нестерук Владимир Викторович	Drug for treatment of anemia associated with chronic kidney disease and method for its obtaining
US20250032494A1 (en)	2021-12-06	2025-01-30	My Personal Therapeutics Ltd	A combination treatment for cancer
WO2024171019A1 (en) *	2023-02-13	2024-08-22	Alembic Pharmaceuticals Limited	Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en)	2023-12-21	2025-06-26	Synthon B.V.	Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4727077A (en)	1985-02-20	1988-02-23	Ishihara Sangyo Kaisha Ltd.	Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (en) *	1985-03-08	1986-09-11	Ishihara Sangyo Kaisha Ltd	Benzoylurea compound, production thereof, and anticancer drug containing same
US5559235A (en)	1991-10-29	1996-09-24	Glaxo Wellcome Inc.	Water soluble camptothecin derivatives
US5342947A (en)	1992-10-09	1994-08-30	Glaxo Inc.	Preparation of water soluble camptothecin derivatives
US5681835A (en)	1994-04-25	1997-10-28	Glaxo Wellcome Inc.	Non-steroidal ligands for the estrogen receptor
US5491237A (en)	1994-05-03	1996-02-13	Glaxo Wellcome Inc.	Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en)	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
KR100883289B1 (en) *	2004-06-11	2009-02-11	니뽄 다바코 산교 가부시키가이샤	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido [2,3-D] pyrimidine derivatives and related compounds for cancer treatment
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
US7955622B2 (en) *	2006-10-13	2011-06-07	Actavis Group Ptc Hf	Controlled-release galantamine formulations
EP2086518A2 (en) *	2006-11-09	2009-08-12	Gilead Colorado, Inc.	Darusentan oral dosage form
JO2985B1 (en) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	MAPK/ERK Kinase Inhibitors
UY30892A1 (en)	2007-02-07	2008-09-02	Smithkline Beckman Corp	AKT ACTIVITY INHIBITORS
ECSP077628A (en)	2007-05-03	2008-12-30	Smithkline Beechman Corp	NEW PHARMACEUTICAL COMPOSITION
CA2694646C (en) *	2007-07-30	2017-09-05	Ardea Biosciences, Inc.	Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
MX2010003200A (en) *	2007-09-25	2010-04-30	Teva Pharma	Stable imatinib compositions.
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
KR20110031370A (en)	2008-07-08	2011-03-25	베타 파마, 인크.	Hydrochloric acid IOCOTINI, synthesis, crystalline form, pharmaceutical composition and use thereof
BR112012006693A2 (en)	2009-09-23	2015-09-08	Glaxosmithkline Llc	combination
BR112012006485A2 (en)	2009-09-23	2015-09-08	Glaxosmithkline Llc	combination
WO2011038380A2 (en) *	2009-09-28	2011-03-31	Glaxosmithkline Llc	Combination
HUE060206T2 (en) *	2009-10-16	2023-02-28	Novartis Ag	Combination comprising an mek inhibitor and a b-raf inhibitor
CN104382906A (en)	2009-11-17	2015-03-04	葛兰素史密斯克莱有限责任公司	Combination
JP5903433B2 (en) *	2010-08-26	2016-04-13	ノバルティスアーゲー	Pharmaceutical combination of VEGFR inhibitor and MEK inhibitor useful for the treatment of cancer
TWI505828B (en)	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	Novel pharmaceutical composition
US8977217B1 (en)	2013-02-20	2015-03-10	Triquint Semiconductor, Inc.	Switching device with negative bias circuit
CZ2015278A3 (en)	2015-04-24	2016-11-02	Zentiva, K.S.	Trametinib crystalline forms

2011
- 2011-12-16 TW TW100146692A patent/TWI505828B/en active
- 2011-12-18 JO JOP/2011/0385A patent/JO3594B1/en active
- 2011-12-19 UY UY0001033818A patent/UY33818A/en active IP Right Grant
- 2011-12-19 AR ARP110104773A patent/AR084102A1/en not_active Application Discontinuation
- 2011-12-20 PL PL22209104.3T patent/PL4159204T3/en unknown
- 2011-12-20 MA MA36106A patent/MA34883B1/en unknown
- 2011-12-20 SG SG2013044037A patent/SG191054A1/en unknown
- 2011-12-20 US US13/330,949 patent/US8580304B2/en active Active
- 2011-12-20 AU AU2011349422A patent/AU2011349422B2/en active Active
- 2011-12-20 PH PH1/2013/501209A patent/PH12013501209A1/en unknown
- 2011-12-20 PT PT222091043T patent/PT4159204T/en unknown
- 2011-12-20 SI SI201131918T patent/SI2654736T1/en unknown
- 2011-12-20 LT LTEP22209104.3T patent/LT4159204T/en unknown
- 2011-12-20 JP JP2013546310A patent/JP6126014B2/en active Active
- 2011-12-20 KR KR1020137019029A patent/KR101911109B1/en active Active
- 2011-12-20 RS RS20240519A patent/RS65497B1/en unknown
- 2011-12-20 HU HUE22209107A patent/HUE066526T2/en unknown
- 2011-12-20 SI SI201132109T patent/SI4159204T1/en unknown
- 2011-12-20 DK DK22209104.3T patent/DK4159204T3/en active
- 2011-12-20 WO PCT/US2011/066021 patent/WO2012088033A2/en not_active Ceased
- 2011-12-20 ES ES11849974T patent/ES2820536T3/en active Active
- 2011-12-20 LT LTEP22209107.6T patent/LT4159205T/en unknown
- 2011-12-20 PL PL11849974T patent/PL2654736T3/en unknown
- 2011-12-20 EP EP22209104.3A patent/EP4159204B1/en active Active
- 2011-12-20 PT PT118499748T patent/PT2654736T/en unknown
- 2011-12-20 MX MX2013007073A patent/MX2013007073A/en active IP Right Grant
- 2011-12-20 DK DK11849974.8T patent/DK2654736T3/en active
- 2011-12-20 PL PL22209107.6T patent/PL4159205T3/en unknown
- 2011-12-20 EA EA201390913A patent/EA025198B1/en not_active IP Right Cessation
- 2011-12-20 CN CN201180066851.0A patent/CN103998041B/en active Active
- 2011-12-20 HR HRP20240564TT patent/HRP20240564T1/en unknown
- 2011-12-20 HU HUE22209104A patent/HUE066525T2/en unknown
- 2011-12-20 EP EP22209107.6A patent/EP4159205B1/en active Active
- 2011-12-20 PT PT222091076T patent/PT4159205T/en unknown
- 2011-12-20 SI SI201132108T patent/SI4159205T1/en unknown
- 2011-12-20 HR HRP20201409TT patent/HRP20201409T1/en unknown
- 2011-12-20 FI FIEP22209104.3T patent/FI4159204T3/en active
- 2011-12-20 HU HUE11849974A patent/HUE050788T2/en unknown
- 2011-12-20 LT LTEP11849974.8T patent/LT2654736T/en unknown
- 2011-12-20 BR BR112013015602-3A patent/BR112013015602B1/en active IP Right Grant
- 2011-12-20 DK DK22209107.6T patent/DK4159205T3/en active
- 2011-12-20 UA UAA201309128A patent/UA113158C2/en unknown
- 2011-12-20 RS RS20240518A patent/RS65496B1/en unknown
- 2011-12-20 CA CA2822701A patent/CA2822701C/en active Active
- 2011-12-20 HR HRP20240563TT patent/HRP20240563T1/en unknown
- 2011-12-20 PE PE2013001442A patent/PE20140040A1/en active IP Right Grant
- 2011-12-20 EP EP20179788.3A patent/EP3808343A1/en active Pending
- 2011-12-20 MY MYPI2013701038A patent/MY170501A/en unknown
- 2011-12-20 ES ES22209107T patent/ES2985024T3/en active Active
- 2011-12-20 EP EP11849974.8A patent/EP2654736B1/en not_active Revoked
- 2011-12-20 FI FIEP22209107.6T patent/FI4159205T3/en active
- 2011-12-20 NZ NZ612157A patent/NZ612157A/en unknown
- 2011-12-20 ES ES22209104T patent/ES2982775T3/en active Active
- 2011-12-20 US US13/991,705 patent/US20130266649A1/en not_active Abandoned
2013
- 2013-06-07 ZA ZA2013/04189A patent/ZA201304189B/en unknown
- 2013-06-10 IL IL226855A patent/IL226855A/en active IP Right Grant
- 2013-06-18 CL CL2013001779A patent/CL2013001779A1/en unknown
- 2013-06-18 DO DO2013000138A patent/DOP2013000138A/en unknown
- 2013-07-19 CR CR20130352A patent/CR20130352A/en unknown
- 2013-10-02 US US14/044,139 patent/US9271941B2/en active Active
- 2013-12-11 US US14/103,193 patent/US9155706B2/en active Active
- 2013-12-11 US US14/103,092 patent/US9399021B2/en active Active
2017
- 2017-01-19 JP JP2017007796A patent/JP2017137299A/en not_active Withdrawn
2020
- 2020-09-24 CY CY20201100905T patent/CY1123376T1/en unknown
2021
- 2021-05-27 AR ARP210101433A patent/AR122185A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
RS65497B1 (en)	2024-06-28
HRP20240564T1 (en)	2024-09-27
EP4159204B1 (en)	2024-02-14
CN103998041B (en)	2016-08-17
CA2822701C (en)	2018-10-23
US9399021B2 (en)	2016-07-26
PL2654736T3 (en)	2020-12-14
US20120183613A1 (en)	2012-07-19
TW201249441A (en)	2012-12-16
EA201390913A1 (en)	2014-04-30
US20140154316A1 (en)	2014-06-05
ES2985024T3 (en)	2024-11-04
CY1123376T1 (en)	2021-12-31
LT4159205T (en)	2024-05-10
EP2654736A2 (en)	2013-10-30
SI2654736T1 (en)	2020-10-30
EP4159204A1 (en)	2023-04-05
US9271941B2 (en)	2016-03-01
LT4159204T (en)	2024-05-10
EP2654736A4 (en)	2015-04-22
HRP20240563T1 (en)	2024-08-16
CL2013001779A1 (en)	2014-06-27
WO2012088033A3 (en)	2014-03-13
US20140099365A1 (en)	2014-04-10
PT4159204T (en)	2024-05-07
DOP2013000138A (en)	2013-11-30
AR122185A2 (en)	2022-08-24
MA34883B1 (en)	2014-02-01
RS65496B1 (en)	2024-06-28
DK4159204T3 (en)	2024-05-21
EP2654736B1 (en)	2020-07-01
BR112013015602A2 (en)	2017-02-21
CR20130352A (en)	2013-12-18
US9155706B2 (en)	2015-10-13
KR101911109B1 (en)	2018-10-23
TWI505828B (en)	2015-11-01
DK4159205T3 (en)	2024-05-13
PT4159205T (en)	2024-05-08
AU2011349422B2 (en)	2015-12-10
PE20140040A1 (en)	2014-02-26
US20140037726A1 (en)	2014-02-06
PH12013501209A1 (en)	2013-07-29
CA2822701A1 (en)	2012-06-28
EP4159205A1 (en)	2023-04-05
HUE050788T2 (en)	2021-01-28
ES2820536T3 (en)	2021-04-21
FI4159204T3 (en)	2024-04-22
IL226855A (en)	2017-04-30
EA025198B1 (en)	2016-11-30
MX2013007073A (en)	2013-09-26
UA113158C2 (en)	2016-12-26
PT2654736T (en)	2020-09-24
SI4159205T1 (en)	2024-06-28
US8580304B2 (en)	2013-11-12
PL4159204T3 (en)	2024-07-01
WO2012088033A2 (en)	2012-06-28
US20130266649A1 (en)	2013-10-10
AU2011349422A1 (en)	2013-05-02
KR20130130028A (en)	2013-11-29
JO3594B1 (en)	2020-07-05
HUE066526T2 (en)	2024-08-28
SI4159204T1 (en)	2024-06-28
FI4159205T3 (en)	2024-04-23
ES2982775T3 (en)	2024-10-17
SG191054A1 (en)	2013-08-30
DK2654736T3 (en)	2020-09-14
JP2014510704A (en)	2014-05-01
ZA201304189B (en)	2014-02-26
MY170501A (en)	2019-08-08
NZ612157A (en)	2015-05-29
JP2017137299A (en)	2017-08-10
EP3808343A1 (en)	2021-04-21
AR084102A1 (en)	2013-04-24
LT2654736T (en)	2020-09-25
EP4159205B1 (en)	2024-02-14
UY33818A (en)	2012-07-31
BR112013015602B1 (en)	2022-03-03
JP6126014B2 (en)	2017-05-10
CN103998041A (en)	2014-08-20
HRP20201409T1 (en)	2020-11-27
HUE066525T2 (en)	2024-08-28

Publication	Publication Date	Title
IL245326A0 (en)	2016-06-30	Pharmaceutical composition
ZA201304189B (en)	2014-02-26	Novel pharmaceutical composition
LT2619182T (en)	2017-01-25	Pharmaceutical composition
IL225457A0 (en)	2013-06-27	Pharmaceutical composition
LT2616076T (en)	2016-10-10	Pharmaceutical compositions
PT2579858E (en)	2014-07-18	Ivabradine-containing pharmaceutical composition
ZA201301920B (en)	2013-10-30	Pharmaceutical composition
GB201010453D0 (en)	2010-08-04	Pharmaceutical composition
IL226554A (en)	2017-12-31	Pharmaceutical compositions comprising alisporivir
SG10201508982TA (en)	2015-12-30	Pharmaceutical compositions
IL221501A (en)	2016-11-30	Pharmaceutical composition comprising myramistin
EP2560678A4 (en)	2013-09-18	Pharmaceutical compositions
GB201001911D0 (en)	2010-03-24	Pharmaceutical composition
GB201019775D0 (en)	2011-01-05	Pharmaceutical composition
HU1000006D0 (en)	2010-03-01	Improved pharmaceutical composition
GB201005403D0 (en)	2010-05-12	Novel pharmaceutical compositions
GB201008590D0 (en)	2010-07-07	Pharmaceutical compositions
SG10201509530YA (en)	2015-12-30	Pharmaceutical compositions